Moderna

Moderna's mRNA vaccine for mpox shows higher efficacy than Bavarian Nordics' Jynneos in preventing severe disease and reducing virus levels in monkeys, according to a study published in Cell. The vaccine also reduces viral replication and lesion formation, potentially limiting spread. Moderna is currently conducting a Phase I/II trial in the UK, with results expected in mid-2025.

FDA approves new Pfizer and Moderna COVID-19 vaccines for fall, targeting KP.2 variant. Symptoms remain similar to previous variants, with high risk of complications. mRNA technology promotes immune response, differing from traditional vaccines. CDC recommends updated vaccine for all Americans six months and older. Limited vaccine supply available for uninsured and underinsured patients.

FDA approved updated COVID-19 vaccines targeting Omicron variants JN.1 and KP.2 for ages 12+, with mRNA vaccines by Moderna and Pfizer for ages 6 months+. CDC recommends vaccination for everyone 6 months+, emphasizing importance for high-risk groups. Timing and doses depend on vaccination status. JN.1, KP.2, KP.3, and KP.3.1.1 are circulating variants. Pharmacies like CVS and Kroger offer the vaccines.

Moderna is close to securing EU approval for its updated COVID-19 vaccine, Spikevax, targeting the JN.1 variant. The EMA's CHMP recommended authorization, pending European Commission decision for the 2024-2025 season. Moderna's vaccine aims to enhance antibody responses against JN.1 and related lineages for individuals aged six months and older. The company has already secured approvals in Japan, Taiwan, and the UK, with ongoing reviews elsewhere. Moderna participates in the EU's HERA tendering process, potentially expanding vaccine reach. The company's mRNA platform supports rapid development of vaccines and therapeutics.

Moderna's updated COVID-19 mRNA vaccine, Spikevax, targeting the JN.1 variant, receives positive opinion from CHMP for authorization in EU for ages 6 months and over for autumn/winter 2024-2025 season, based on efficacy and safety data. Moderna has similar approvals in Japan, Taiwan, and the UK, and is participating in EU tender for Covid vaccines.

Moderna's updated COVID-19 vaccine targeting the JN.1 strain of Omicron receives a positive opinion from the EMA's CHMP, paving the way for marketing authorization in the EU for the 2024-2025 respiratory season.

Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 recommended by EMA's CHMP for EU authorization, pending EC decision for 2024-2025 season.

Moderna announced EMA's CHMP adopted a positive opinion recommending marketing authorization for an updated COVID-19 mRNA vaccine Spikevax targeting SARS-CoV-2 variant JN.1, for individuals six months and older. The European Commission will decide on its use for the 2024-2025 autumn/winter season.

Moderna's COVID-19 mRNA vaccine for SARS-CoV-2 variant JN.1 received a positive opinion from EMA's CHMP, recommended for the 2024-2025 EU vaccination season, pending final authorization. This vaccine is part of Moderna's strategy to adapt to evolving variants, with approvals already in Japan, Taiwan, the UK, and the US.